Correction to: A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

Abstract

Key summary points Why carry out this study? Migraine is a common condition affecting approximately 30 million adults and 9 million children and adolescents in the US; symptoms and disability during an attack are managed with acute treatments, including simple analgesics, nonsteroidal anti-inflammatory drugs, opioid analgesics, butalbital-containing analgesic products, and over-the-counter combinations of analgesics and caffeine, as well as prescription migraine-specific agents which historically have included triptans and ergot derivatives (e.g., dihydroergotamine). Triptans are commonly used for acute treatment of migraine attacks. However, some patients may not be adequately managed with triptans due to lack of efficacy; intolerable side effects known as ‘‘triptan sensations’’ (including nausea, fatigue, malaise, rapid heart rate, feelings of tingling, numbness, warmth, and chest/neck pressure or tightness); and safety concerns for those with a history of vascular disease, multiple risk factors for vascular disease (such as hypertension and diabetes), and during pregnancy. The US Food and Drug Administration (FDA) has recently approved three new acute treatments for migraine – rimegepant (NURTECTM ODT) and ubrogepant (UBRELVY ), both CGRP receptor antagonists, and lasmiditan (REYVOW ), a 5-HT1F receptor agonist – which the American Headache Society (AHS) has recommended for patients who have contraindications to triptans or who have failed to respond to or tolerate at least two oral triptans. Understanding the size of the patient population likely to use new treatments may be of interest to payers and health systems; in this study, we therefore developed a conceptual framework for estimating anticipated use of new acute therapies, based on a targeted literature review (TLR) and insights from clinical experience. The original article can be found online at https://doi. org/10.1007/s12325-021-01781-z.